CNS Pharmaceuticals Inc. Soars Amid Strategic Financial Moves and Drug Development Breakthroughs
CNS Pharmaceuticals Inc’s stock has surged 73% to $2.10, driven by a $5 million public offering and advancements in drug development, including the acquisition of Orphan Drug Designation for its novel abeotaxane TPI 287.
3 minutes to read